Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Denali Therapeutics Inc. on June 2, 2021. The record date for the meeting was April 12, 2021, with 121,177,045 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
112,684,753 shares were represented at the meeting, constituting 92.99% of the outstanding common stock entitled to vote. The following matters were approved:
- Proposal 1 (Election of Directors): Four Class I directors were elected to serve until the 2024 annual meeting.
- Douglas Cole, M.D.: 94,579,825 For
- Jay Flatley: 94,448,214 For
- Marc Tessier-Lavigne, Ph.D.: 94,508,862 For
- Nancy A. Thornberry: 102,773,240 For
- Proposal 2 (Ratification of Auditors): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2021 (112,610,879 For).
- Proposal 3 (Executive Compensation): Stockholders approved the advisory vote on executive compensation (100,992,741 For).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class I directors (until 2024).
- Confirm the appointment of Ernst & Young LLP as the auditor for the 2021 fiscal year.
- Note the high level of shareholder participation (92.99% of outstanding shares represented).
- Review the full Proxy Statement for details on executive compensation approved in Proposal 3.